help button home button The Oncologist
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
The Oncologist, Vol. 13, No. suppl_3, 27-32, May 2008; doi:10.1634/theoncologist.13-S3-27
© 2008 AlphaMed Press

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow eLetters: Submit a response to this article
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Spano, J.-P.
Right arrow Articles by Khayat, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Spano, J.-P.
Right arrow Articles by Khayat, D.

Treatment Options for Anemia, Taking Risks into Consideration: Erythropoiesis-Stimulating Agents Versus Transfusions

Jean-Philippe Spano, David Khayat

Department of Medical Oncology, Pitié-Salpétrière Hospital, Pierre & Marie Curie University, Paris, France

Key Words. Anemia • Erythropoiesis-stimulating agents • Transfusions

Correspondence: Jean-Philippe Spano, M.D., Ph.D., Département d'Oncologie Médicale, Groupe Hospitalier Pitié-Salpétrière, 47 Boulevard de l'Hôpital, 75013 Paris, France. Telephone: 33-1-42-16-04-52; Fax: 33-1-42-16-04-65; e-mail: jean-philippe.spano{at}psl.aphp.fr

Disclosure: No potential conflicts of interest were reported by the author, planners, reviewers, or staff managers of this article.

Erythropoiesis-stimulating agents are indicated for the treatment of chemotherapy induced-anemia in cancer patients. Controlled clinical studies have shown that epoetin alfa consistently and significantly increases levels of hemoglobin (Hb), decreases the need for RBC transfusion, and improves the quality of life that is of such importance in cancer patients with a limited life expectancy. The rise achieved in Hb level correlates with an improvement in quality of life. Studies have also demonstrated that earlier initiation of epoetin therapy (i.e., starting treatment at an Hb level of 10–11 g/dl rather than waiting for Hb to fall to <10 g/dl) is associated with a faster achievement of an optimal Hb level, a lower transfusion requirement, and a maintained quality of life.




This article has been cited by other articles:


Home page
 The OncologistHome page
M. S. Aapro
Editorial: Anemia Management with Erythropoiesis-Stimulating Agents: A Risk-Benefit Update
Oncologist, May 1, 2008; 13(suppl_3): 1 - 3.
[Full Text] [PDF]


HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS


Copyright © 2008 by AlphaMed Press.